TP53 and undifferentiated (embryonal) sarcoma: To our knowledge, this is the first case of SLMNs and undifferentiated sarcoma after treatment of ovarian mucinous cystadenocarcinoma of the ovary with KRAS, TP53, MLL2 and NF1 mutation.